• The global Autism Drug Market is poised for substantial growth through 2032, registering a CAGR of 5.9% from 2025 to 2032.
• The increasing need for therapeutic options addressing core and associated symptoms of ASD, such as irritability, hyperactivity, and repetitive behaviors, is boosting demand for antipsychotics, stimulants, and SSRIs.
• The market benefits from progress in novel drug discovery, rising investment in pediatric neurological research, and growing acceptance of personalized medicine approaches.
• Growth in neurodevelopmental disorder-focused healthcare infrastructure, supportive government initiatives, and increasing clinical trials targeting rare autism-related genetic mutations are expected to further strengthen market performance, particularly in emerging economies
